** Intuitive Surgical ISRG.O beat Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by growing demand for its surgical robots used in minimally invasive procedures

** ISRG shares up 0.6% at $514 premarket

SOLID MOMENTUM TO CONTINUE

** J.P.Morgan ("overweight", PT: $605) expects latest generation da Vinci5 to help drive double-digit sales growth in 2025 and beyond, despite existing macro challenges

** Piper Sandler ("overweight", PT: $595) says ISRG is well-positioned to be a beat-and-raise story going forward as it sees co's outlook as conservative

** RBC Capital Markets ("outperform," PT: $615) says Q2 earnings should help restore investor confidence as ISRG continues to scale up its key product even as broader macroeconomic challenges persist

** Morgan Stanley ("overweight," PT: $650) sees co's expansion into new areas, including endoluminal, cardiac, as positive

** Brokerage adds, "over time we expect ISRG to be able to drive stronger clinical outcomes and bend the cost curve of key soft tissue surgeries to take the majority of volumes from many laparoscopic procedures"

(Reporting by Kanchana Chakravarty in Bengaluru)

((Kanchana.Chakravarty@thomsonreuters.com))